Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cullinan Therapeutics Inc
(NQ:
CGEM
)
17.61
-0.19 (-1.07%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cullinan Therapeutics Inc
< Previous
1
2
3
4
Next >
Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst
August 09, 2024
Merck has agreed to acquire CN201, a bispecific antibody from Curon Biopharmaceutical, for $700 million. This acquisition aims to advance Merck's pipeline for treating B-cell malignancies and...
Via
Benzinga
CGEM Stock Earnings: Cullinan Therapeutics Misses EPS for Q2 2024
August 08, 2024
CGEM stock results show that Cullinan Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
June 01, 2024
Objective response rate of 39% with manageable safety profile in patients with non-small cell lung cancer (NSCLC) harboring EGFR Exon 20 insertion mutations treated with zipalertinib who had progressed...
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Oncology: Q4 Earnings Insights
March 14, 2024
Via
Benzinga
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
May 24, 2024
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
May 23, 2024
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q1 2024
May 15, 2024
CGEM stock results show that Cullinan Oncology beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 15, 2024
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 29, 2024
Via
Benzinga
Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday
April 29, 2024
Via
Benzinga
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
April 29, 2024
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
April 26, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
April 26, 2024
Via
Benzinga
Skechers Reports Upbeat Earnings, Joins Tutor Perini, AppFolio, Newell Brands And Other Big Stocks Moving Higher On Friday
April 26, 2024
Via
Benzinga
Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?
April 24, 2024
Explore the use of Amgen's Blincyto in treating severe systemic sclerosis, shedding light on Cullinan Therapeutics' CLN-978 potential for autoimmune diseases, particularly systemic lupus...
Via
Benzinga
Hilton Worldwide Reports Upbeat Results, Joins Hasbro, Vertiv Holdings And Other Big Stocks Moving Higher On Wednesday
April 24, 2024
Via
Benzinga
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
April 24, 2024
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
United Airlines Reports Upbeat Results, Joins Children's Place, Interactive Brokers And Other Big Stocks Moving Higher On Wednesday
April 17, 2024
U.S. stocks were lower, with the Dow Jones index falling over 50 points on Wednesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
April 17, 2024
Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings.
Via
Benzinga
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
April 16, 2024
Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates.
Via
Benzinga
Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity
April 16, 2024
Cullinan shifts focus to autoimmune diseases with CLN-978, targeting systemic lupus erythematosus. Initial trial results show potential for treatment with a differentiated safety profile.
Via
Benzinga
UnitedHealth Reports Upbeat Earnings, Joins Cullinan Oncology, Ericsson And Other Big Stocks Moving Higher On Tuesday
April 16, 2024
U.S. stocks were mostly higher, with the Dow Jones index gaining over 100 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Cullinan Management Inc. (NASDAQ: CGEM) Records 52-Week High Tuesday Morning
April 16, 2024
Via
Investor Brand Network
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 16, 2024
Via
Benzinga
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
April 16, 2024
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
April 16, 2024
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q4 2023
March 14, 2024
CGEM stock results show that Cullinan Oncology beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
March 14, 2024
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
March 01, 2024
From
Cullinan Oncology, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.